Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: Report of 12 cases and a review of the literature

British Journal of Cancer

Volumn 82, Issue 2, 2000, Pages 291-294

  Pelgrims, J ^a   De Vos, F ^a   Van Den Brande, J ^a   Schrijvers, D ^a   Prove A ^a   Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Encephalopathy; Ifosfamide; Methylene blue

Indexed keywords

IFOSFAMIDE; METHYLENE BLUE; NEUROPROTECTIVE AGENT;

ARTICLE; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; NEUROPROTECTION; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; METHYLENE BLUE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0033985032     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0917     Document Type: Article

References (20)

1. Aeschlimann C, Cerny T and Küpfer A (1996) Inhibition of (mono) amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Disp 24: 1336-1339
2. Aeschlimann C, Küpfer A, Schefer H and Cerny T (1998) Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Disp 26: 883-890
3. Alonso JL, Nieto Y, López JA, Martín M und Díaz-Rubio E (1996) Ifosfamide encephalopathy and methylene blue: a case report. Ann Oncol 7: 643-645
4. Cerny T, Castiglione M, Brunner K, Küpfer A, Martinelli G and Lind M (1990) Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 335: 175
5. Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB and Morrow P (1991) Ifosfamide-induced neurotoxicity. Gynecol Oncol 42: 193-196
6. Demandt M and Wandt H (1996) Erfolgreiche Behandlung von Ifosfamid-bedingten zentralnervösen Nebenwirkungen mit Methylenblau. Dtsch Med Wochenschr 121: 575
7. DiMaggio JR, Brown R, Baile WF and Schapira D (1994) Hallucinations and ifosfamide-induced neurotoxicity. Cancer 73: 1509-1514
8. Ferrero JM, Eftekari P, Largillier R, Dreyfus G and Namer M (1995) Traitement d'une encéphalopathie à l'ifosfamide par le bleu de méthyléne. Bull Cancer 82: 598-599
9. Harpey JP, Charpentier C and Coudé M (1986) Methylene blue for riboflavin-unresponsive glutarica ciduria type II. Lancet I: 391
10. Hrushesky WJ, Olshefski R, Wood P, Meshnick S and Eaton JW (1985) Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet 1: 565-567
11. Kaijser GP, Beijnen JH, Bult A and Underberg WJM (1994) Ifosfamide metabolism and pharmacokinetics. Anticancer Research 14: 517-532
12. Koschuth A, Späth-Schwalbe E and Possinger K (1996) Methylenblau bei Ifosfamid-induzierter Enzephalopathie. Dtsch Med Wochenschr 121: 1210
13. Küpfer A, Aeschlimann C, Wermuth B and Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 343: 763-764
14. Küpfer A, Aeschlimann C and Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50, 249-252
15. Kurowski V, Cerny T, Küpfer A and Wagner T (1991) Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117: S148-S153
16. Merimsky O, Reider-Groswasser I, Wigler N and Chaitchik S (1992) Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 86: 521-525
17. Pratt OE, Rooprai HK, Shaw GK and Thomson AD (1990) The genesis of alcoholic brain tissue injury. Alcohol Alcohol 25: 217-230
18. Van Tongelen K and Hawthorn J (1994) A Practical Guide to EORTC Studies. EORTC: Brussels
19. Watkin SW, Husband DJ, Green JA and Warenius HM (1989) Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 25: 1303-1310
20. Zulian GB, Tullen E and Maton B (1995) Methylene blue for ifosfamide associated encephalopathy. N Engl J Med 332: 1239-1240